A Study of PT0253 in Participants With KRAS G12D Mutated Advanced Solid Tumors

ClinicalTrials.gov ID: NCT06797336

Public ClinicalTrials.gov record NCT06797336. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Sep 11, 2026, 5:04 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 1, Open-Label Dose Escalation and Expansion Study of PT0253 in Participants With KRAS G12D Mutated Advanced Solid Tumors

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The primary purpose of this study is to evaluate the safety and tolerability, determine the maximally tolerated dose (MTD) and/or recommended Phase 2 dose(s) (RP2D) of PT0253 in adult participants with Kirsten rat sarcoma viral oncogene homolog (KRAS) G12D mutated advanced solid tumors as monotherapy.

Study identification

NCT ID: NCT06797336
Recruitment status: Recruiting
Study type: Interventional
Phase: Phase 1
Lead sponsor: PAQ Therapeutics, Inc.; Industry
Enrollment: 240 participants

Conditions and interventions

Conditions

Solid Tumor

Interventions

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Dec 18, 2024
Primary completion: Dec 14, 2026
Completion: Jun 15, 2027
Last update posted: Aug 11, 2026

2024 – 2027

United States locations

U.S. sites: 9
U.S. states: 7
U.S. cities: 7

Facility	City	State	ZIP	Site status
START Los Angeles	Los Angeles	California	90025	Recruiting
Dana Farber/Massachusetts General Hospital, Inc	Boston	Massachusetts	02215	Recruiting
START Midwest	Grand Rapids	Michigan	49546	Recruiting
SCRI Lake Mary	Nashville	Tennessee	37203	Withdrawn
SCRI Oncology Partners	Nashville	Tennessee	37203	Withdrawn
New Experimental Therapeutics of San Antonio LLC	San Antonio	Texas	78229	Recruiting
START - South Texas Accelerated Research Therapeutics, LLC	San Antonio	Texas	78229	Recruiting
START Mountain Region	West Valley City	Utah	84119	Recruiting
NEXT Virginia	Fairfax	Virginia	22031	Recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 6 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT06797336, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Aug 11, 2026 · Synced Sep 11, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT06797336 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →